Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 6

Sleep disturbances and suicide risk: A review of the literature

Authors Rebecca A Bernert, Thomas E Joiner

Published 15 January 2008 Volume 2007:3(6) Pages 735—743

DOI https://dx.doi.org/10.2147/NDT.S1248

Rebecca A Bernert, Thomas E Joiner

Department of Psychology, Florida State University, Tallahassee, FL, USA

Abstract: A growing body of research indicates that sleep disturbances are associated with suicidal ideation and behaviors. This article (1) provides a critical review of the extant literature on sleep and suicidality and (2) addresses shared underlying neurobiological factors, biological and social zeitgebers, treatment implications, and future directions for research. Findings indicate that suicidal ideation and behaviors are closely associated with sleep complaints, and in some cases, this association exists above and beyond depression. Several cross-sectional investigations indicate a unique association between nightmares and suicidal ideation, whereas the relationship between insomnia and suicidality requires further study. Underlying neurobiological factors may, in part, account for the relationship between sleep and suicide. Serotonergic neurotransmission appears to play a critical role in both sleep and suicide. Finally, it remains unclear whether or not sleep-oriented interventions may reduce risk for suicidal behaviors. Unlike other suicide risk factors, sleep complaints may be particularly amenable to treatment. As a warning sign, disturbances in sleep may thus be especially useful to research and may serve as an important clinical target for future suicide intervention efforts.

Keywords: suicidality, sleep, nightmares, suicide risk factors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Surface modifications of silica nanoparticles are crucial for their inert versus proinflammatory and immunomodulatory properties

Marzaioli V, Aguilar-Pimentel JA, Weichenmeier I, Luxenhofer G, Wiemann M, Landsiedel R, Wohlleben W, Eiden S, Mempel M, Behrendt H, Schmidt-Weber C, Gutermuth J, Alessandrini F

International Journal of Nanomedicine 2014, 9:2815-2832

Published Date: 5 June 2014

Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

David J Muzina

Neuropsychiatric Disease and Treatment 2009, 5:279-288

Published Date: 19 May 2009

Did depressive symptoms affect recognition of emotional prosody in Parkinson’s disease?

Adriana Vélez Feijó, Carlos RM Rieder, Márcia LF Chaves

Neuropsychiatric Disease and Treatment 2008, 4:669-674

Published Date: 6 June 2008

White versus gray matter function as seen on neuropsychological testing following bone marrow transplant for acute leukemia in childhood

Fiona S Anderson, Alicia S Kunin-Batson, Joanna L Perkins, K Scott Baker

Neuropsychiatric Disease and Treatment 2008, 4:283-288

Published Date: 8 February 2008

Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy

Stéphane Auvin

Neuropsychiatric Disease and Treatment 2007, 3:729-734

Published Date: 15 January 2008

Urban–rural differences in pediatric traumatic head injuries: A prospective nationwide study

Jonas G Halldorsson, Kjell M Flekkoy, Kristinn R Gudmundsson, Gudmundur B Arnkelsson, Eirikur Orn Arnarson

Neuropsychiatric Disease and Treatment 2007, 3:935-941

Published Date: 15 January 2008

Cognitive decline tracks motor progression and not disease duration in Parkinson patients

BD Riggeal, GP Crucian, P Seignourel, CE Jacobson IV, MS Okun, et al

Neuropsychiatric Disease and Treatment 2007, 3:955-958

Published Date: 15 January 2008

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

Baptist Gallwitz

Vascular Health and Risk Management 2007, 3:203-210

Published Date: 15 May 2007